307 results about "Prokaryotic cells" patented technology

The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.

The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more proteins selected from the group consisting of NPT1, PNC1, NMA1 and NMA2. Another method comprises modulating the level of nicotinamide in the cell.

A fluidic device for cell electroporation, cell lysis, and cell electrofusion based on constant DC voltage and geometric variation is provided. The fluidic device can be used with prokaryotic or eukaryotic cells. In addition, the device can be used for electroporative delivery of compounds, drugs, and genes into prokaryotic and eukaryotic cells on a microfluidic platform.

Microfluidic devices fabricated from paper that has been covalently modified to increase its hydrophobicity, as well as methods of making and using thereof are provided herein. The devices are typically small, portable, flexible, and both easy and inexpensive to fabricate. Microfluidic devices contain a network of microfluidic components, including microfluidic channels, microfluidic chambers, microwells, or combinations thereof, designed to carry, store, mix, react, and/or analyze liquid samples. The microfluidic channels may be open channels, closed channels, or combinations thereof. The microfluidic devices may be used to detect and/or quantify an analyte, such as a small molecules, proteins, lipids polysaccharides, nucleic acids, prokaryotic cells, eukaryotic cells, particles, viruses, metal ions, and combinations thereof.

The present invention discloses a three-dimensional porous growth surface made from polysaccharide material, especially the alginic acid, to enhance cell growth surface, promote cell adherence, immobilization and propagation, maintain surface structure integrity, enable programmable degradation, and thus increase cellular production. The present invention teaches several methods: a method to enhance the integrity of the growth surface by protecting the growth surface in a rigid solid support; a method of use for enhancing the performance of the surface; and a method of modifying a growth surface for eukaryotic and/or prokaryotic cells comprising the steps of increasing surface area by creating porous and 3-D structure, treating a surface to encourage cell attachment, promoting cell growth and proliferation, and disposing the growth surface in any conventional cell cultivating device. The growth surface is able to program degradation and release the cell/tissue mass after the culture is completed.

The invention belongs to the field of molecular biology and relates to a high-activity T-cell promoter and an application thereof. Particularly, the high-activity T-cell promoter comprises an element 1 and an element 2, wherein the element 1 is an EF1 alpha promoter and/or an EF1 alpha promoter containing an intron; and the element 2 is any one or more of an mCMV promoter, an hCMV promoter and a CD3e promoter. The high-activity T-cell promoter provided by the invention can be used for efficiently expressing a foreign gene in a T cell, has a stable sequence and is free from sequence loss during the transfer process of a prokaryotic cell and a eukaryotic cell. The high-activity T-cell promoter is applicable to driving the high-efficiency expression of the foreign gene, especially a full-length antibody gene, in the T cell during the process of adoptive cellular immunotherapy.

The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine. Further, the invention is directed to methods of inducing an immune response in a mammal comprising administering said bioconjugate vaccines.

The present invention relates to growing and testing any cell type in a multitest format. The present invention is suited for the characterization of microorganisms, as well as animal and plant cells. The present invention is also particularly suited for analysis of phenotypic differences between strains of organisms, including cultures that have been designated as the same genus and species. The present invention is also suited for the analysis of phenotypic differences between cell lines. In some embodiments, a gel forming matrix is used. The present invention provides methods and compositions for the phenotypic analysis and comparison of eukaryotic, as well as prokaryotic cells. The present invention further provides novel methods and compositions for testing the effect(s) of biologically active chemicals on various cells.

The present invention provides nucleic acid molecules, DNA constructs, plasmids, and methods for post-transcriptional regulation of gene expression using RNA molecules to both repress and activate translation of an open reading frame. Repression of gene expression is achieved through the presence of a regulatory nucleic acid element (the cis-repressive RNA or crRNA) within the 5′ untranslated region (5′ UTR) of an mRNA molecule. The nucleic acid element forms a hairpin (stem/loop) structure through complementary base pairing. The hairpin blocks access to the mRNA transcript by the ribosome, thereby preventing translation. In particular, in embodiments of the invention designed to operate in prokaryotic cells, the stem of the hairpin secondary structure sequesters the ribosome binding site (RBS). In embodiments of the invention designed to operate in eukaryotic cells, the stem of the hairpin is positioned upstream of the start codon, anywhere within the 5′ UTR of an mRNA. A small RNA (trans-activating RNA, or taRNA), expressed in trans, interacts with the crRNA and alters the hairpin structure. This alteration allows the ribosome to gain access to the region of the transcript upstream of the start codon, thereby activating transcription from its previously repressed state.

This invention relates to a method for in vivo and in vitro transferring efficiently DNA/RNA coding materials regulating bio-function to cytoplasm or nucleus in eukaryotic or prokaryotic cells using PTD (Protein Transduction Domain) and DNA/RNA binding factor. Particularly, this invention provides a method for in vivo transferring the materials to cells through various routes comprising intramuscular, intraperitoneal, intravein, oral, nasal, subcutaneous, intradermal, mucosal, inhalation. Accordingly, the method of this invention can be used for technology to transfer DNA/RNA to various cell types and express them in the cells transiently or permanently in medicinal applications such as DNA/RNA vaccine and gene therapy, as well as basic applications.

The invention relates to an antitumor cell immunotherapy technology, in particular to preparation of a specific tumor killing cell. The preparation method disclosed by the invention comprises the following steps of: 1, sampling a single prokaryotic cell from peripheral blood; 2, separating a DC (Dendritic Cell) from a T cell; 3, maturing the DC and preparing a DC vaccine; 4, preparing a CIK (Cytokine Induced Killer); 5, preparing a CTL (cytotoxic T lymphocyte); and 6, preparing a specific DC-CIK-CTL cell preparation.

The invention discloses a human FGF21 mutant gene and a method for preparing a recombinant human FGF21 protein. The mutation is carried out on a human FGF21 gene, the base sequence after the mutation is as shown in SEQ IDNO.1, and the expression level of the gene after the mutation in prokaryocytes is significantly improved. The invention further provides a method for improving the expression level of the human FGF21 protein, which comprises the following steps: sequentially connecting a 6 multiplied by His tag gene, an SUMO tag gene, a hydroxylamine cleavage site gene and the human FGF21 mutant gene together, and then obtaining a gene as shown in SEQ ID NO.3; connecting the obtained gene with an expression vector, and obtaining a recombinant expression vector; transforming into host cells; culturing, inducing the expression of the recombinant protein, collecting and purifying the expressed protein, carrying out hydroxylamine cleavage, and further purifying. The method has the advantages of good specificity, high stability, capability of keeping the cleavage activity in a reaction environment system in a wide range, low preparation cost and the like.

The invention provides agilawood sesquiterpenoid synthase protein ASS4 and an encoding gene ASS4 thereof. The protein comprises the following components: (1), protein formed by amino acid sequence shown in SEQ ID NO.2; (2), protein derived from the protein in (1), having the same function as the protein in (1), and formed in the way that one or more amino acids in the amino acid sequence shown in SEQ ID NO.2 are replaced and deleted or added. The invention further provides a preparation method and application of the agilawood sesquiterpenoid synthase protein ASS4. The agilawood sesquiterpenoid synthase protein ASS4, provided by the invention, can be used for catalyzing agilawood sesquiterpenoid externally, the gene ASS4 provided by the invention can be converted into prokaryotic cell, yeast or more advanced eukaryocyte, so as to have corresponding agilawood sesquiterpenoid synthase activity, and the mass production of agilawood sesquiterpenoid can be realized, and the damage to the resource of rare and endangered South China medical aquilaria sinensis is reduced, therefore, the agilawood sesquiterpenoid synthase protein ASS4 has significant economic value and application prospect.

The invention belongs to the technical field of genetic engineering antibodies and particularly relates to a whole human source single chain antibody which is designed and expressed by genetic engineering and has specific affinity towards human vascular endothelial growth factor receptor 2 (VEGFR-2). The invention also provides a nucleotide sequence of heavy chain variable region and light chain variable region immunoglobulin molecules, a nucleotide sequence which comprises the heavy chain variable region and light chain variable region immunoglobulin molecules, an amino acid sequence which comprises variable heavy chain and variable light chain immunoglobulin molecules, and a sequence which corresponds to CDR1, CDR2 and CDR3 of a complementary determining region. The invention also provides a method for generating and expressing the anti-VEGFR-2 single chain antibody, by cycling operations of gathering-elution-gathering, an antibody which has specific affinity towards the human vascular endothelial growth factor is screened, and then the single chain antibody is obtained through a prokaryotic cell secretion and expression system and an affinity purification system. The antibody can be coupled with a detectable substance and therapeutic agent.

Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line is produced by cell fusion of a parental cell and a myeloma cell line and has the same characteristics as the cell line whose strain designation is CmA40 and deposition number is ATCC (To be Provided). The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.

The invention relates to a method for the preparation of DNA virus vectors capable of replication in eukaryotic as well as in prokaryotic cells as well as to DNA virus vectors prepared by this method. Preferably, the method is used to prepare Epstein-Barr virus vectors.

The invention discloses a method for detection of protein-protein interaction through a BRET technology based on bacterial Luciferase. A fluorescent donor clonal pBluescript-pLac::luxAB-MCS is constructed; Green fluorescent protein (GFP) and the like are selected as acceptor proteins; appropriate enzyme cutting sites are chosen in MCS, and three kinds of fluorescent proteins are cloned into the MCS respectively; model bodies of BRET signals are generated; the fluorescence intensity of Luciferase of each of the three BRET model bodies is detected; three model bodies with high fluorescence intensity value are selected as fluorescence donors of BRET signal generation; the expression conditions of the fluorescent proteins are detected through a biological fluorescence microscope (Leica), an appropriate fluorescence acceptor is secleted; The singals of the BRET model bodies are detected through a fluorospectrophotometer. In the method, bacterial Luciferase luxAB as a fluorescence donor for detecting interaction between two proteins and eYFP as a fluorescence acceptor generate BRET signals, and BRET models are constructed. The system can detect dynamic interaction between two proteins in vivo, raise the accuracy of detection of protein-protein interaction, and is an ideal system for detection of protein-protein interaction in prokaryotic cells.

The invention discloses a procaryotic cell non-merge solubility pressing system, which comprises the following steps: building one type auxiliary protein gene or two type auxiliary protein gene and pre-expressing exogenesis goal gene in a transcription unit; proceeding intracellular co-express through each self-contained translational control system of auxiliary protein gene and pre-expressing exogenesis goal gene in the same pronucleus expression host cell; utilizing the auxiliary protein to realize non-merge solubility expression especially to realize non-merge solubility expression with multiple disulfide bond peptide chain. This system can make the expressing quantity of procaryotic cell occupy above 105 of thallus total protein under the normal condition.

The invention initially discovers a nucleotide coded sequence which can improve salt resistance and drought resistance of plants, and a nucleotide coded sequence which is artificially synthesized according to codons preferred by plants. The nucleotide coded sequences construct a recombining carrier containing genes and converts the genes into host cells of prokaryotic cells and eukaryotic cells respectively. Experiments prove that after the genes are expressed in the plant, the obtained transgenic plant has enhanced resistance to salt stress, drought stress and the like.

The invention provides a hybridoma cell line and a monoclonal antibody thereof, an immune detection reagent containing the monoclonal antibody and a kit thereof, and an immune detection method. The hybridoma cell line is prepared by fusing parental cells and myeloma cells, and has the characteristics represented by the cell line with the preservation number of PTA-11304. The parental cell line is prepared by the following steps that: prokaryotic cells are adopted to express non-structural protein coded by a 3ABC gene fragment of foot-and-mouth disease virus, the non-structural protein is adopted as antigen to immunize mice, and spleen cells of the immunized mice are taken out to prepare the parental cell line. The monoclonal antibody produced from the hybridoma cell line can provide specific recognition for the 3ABC peptide of the foot-and-mouth disease virus, and do not generate the non-specific reaction with the swine vesicular disease antiserum.